MRI引导下前列腺穿刺:In-bore与MRI-TRUS融合靶向技术的前列腺癌检出率比较
该回顾性研究纳入223例接受前列腺mpMRI及后续MR引导下穿刺的患者,比较MRI-TRUS融合靶向穿刺与MRI In-bore靶向穿刺对总体前列腺癌和临床显著前列腺癌的检出率及每针芯癌组织百分比。结果显示两种技术检出率无统计学显著差异,但MRI In-bore穿刺的每针芯恶性细胞百分比更高。
要点
- MRI In-bore与MRI-TRUS融合靶向穿刺对前列腺癌和临床显著前列腺癌的检出率无显著差异。
- MRI In-bore穿刺显示更高的每针芯恶性细胞百分比,可能影响风险分层和治疗决策。
- 对适合主动监测或局灶治疗的患者,穿刺方式选择需考虑每针芯癌组织占比。
局限性
- 回顾性研究设计。
- 单中心研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To compare the detection rates of overall prostate cancer (PCa) and clinically significant PCa (csPCa) and the median percentage of cancer per biopsy core between MRI-guided In-bore and MRI-TRUS fusion-targeted biopsy (TBx).
METHODS: In this retrospective study, 223 patients who underwent prostate multiparametric MRI (mpMRI) and subsequent MR-directed biopsy were included. For PCa and csPCa detection rate (DR), contingency tables were tested via the Pearson's chi-squared to explore the variance of the outcome distribution. The percentage of cancer per biopsy core was tested with a two-tailed Mann-Withney test.
RESULTS: One hundred and seventeen and 106 patients underwent MRI-TRUS fusion or MRI In-bore TBx, respectively. 402 MRI biopsy targets were identified, of which 206 (51.2%) were biopsied with the MRI-TRUS TBx and 196 (48.8%) with the MRI In-bore TBx technique. Per-patient PCa and csPCa detection rates were 140/223 (62.8%) and 97/223 (43.5%), respectively. PCa-DR was 73/117 (62.4%) and 67/106 (63.2%) for MRI-TRUS and MRI In-Bore TBx (p = 0.9), while csPCa detection rate reached 50/117 (42.7%) and 47/106 (44.3%), respectively (p = 0.81). The median per-patient percentage of malignant tissue within biopsy cores was 50% (IQR: 27-65%) for PCa and 60% (IQR: 35-68%) for csPCa, with a statistically significant difference between the techniques.
CONCLUSION: No statistically significant difference in the detection rate of MRI In-bore and MRI-TRUS fusion TBx was found. MRI In-bore TBx showed higher per-core percentage of malignant cells.
ADVANCES IN KNOWLEDGE: MRI In-bore biopsy might impact risk stratification and patient management considering the higher per-core percentage of malignant cells, especially for patients eligible for active surveillance or focal therapy.
引用
- Del Monte M, Cipollari S, Del Giudice F, et al. MRI-directed biopsy for primary detection of prostate cancer in a population of 223 men: MRI In-Bore vs MRI-transrectal ultrasound fusion-targeted techniques. Br J Radiol. 2021. PMID: 34609900. doi:10.1259/bjr.20210528
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。